MiddleBrook Pharmaceuticals has brought in Morgan Stanley to advise the company on its strategic alternatives, including a possible sale of the company. MiddleBrook, which develops anti-infectives, says the review will cover everything from staying on its present course to inking new collaborations and selling assets. Executives of the developer--formerly known as Advancis--first announced the company was undergoing a strategic review last spring. The FDA approved its resubmitted application for a strep throat remedy in January.
- see MiddleBrook's release
- read the AFX story